Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma

Table 1

Patient characteristics at admission.

Parameters	Data
Male, n (%)	31 (75.6%)
Mean age, years	58.4 ± 11.4
Lesion types
Right lobe	30 (73.2%)
Left lobe	6 (14.6%)
Bilobar	5 (12.2%)
Symptom duration, months	1.0 (0.3, 7.0)
Recurrence after surgery	5 (12.2%)
Systemic treatments	27 (65.9%)
Targeted therapy	16 (39.0%)
Immunotherapy	2 (4.9%)
Targeted and immunotherapy	9 (22.0%)
Hepatitis B/C virus infection	19 (46.3%)/3 (7.3%)
BCLC stage A/B/C	5 (12.2%)/28 (68.3%)/8 (19.5%)
Child–Pugh class A/B	30 (73.2%)/11 (26.8%)
Multinodular/bulky tumor/diffuse	9 (20.0%)/27 (65.9%)/5 (12.2%)
Portal vein or IVC invasion	9 (22.0%)
Extrahepatic sites	15 (36.6%)
Lung	2 (4.9%)
Lymph node	11 (26.8%)
Bone	1 (2.4%)
Kidney or adrenal gland	3 (7.3%)
Tumor diameter, mm	72.2 ± 34.1
a-Fetoprotein level
Normal (<20 ng/mL)	18 (46.2%)
20–<400 ng/mL	9 (23.1%)
400–10000 ng/mL	7 (17.9%)
>10000 ng/mL	5 (12.8%)

IVC, inferior vena cava.